The company combines ligand research and radiochemistry experts to create rationally designed conjugates that deliver alpha and beta-emitting radionuclide payloads against carefully selected biological targets. They focus on developing a pipeline of radiopharmaceuticals for a range of solid tumor types, with the goal of revolutionizing the use of radio medicines in cancer treatment. Mariana Oncology brings together experts in ligand discovery, radiochemistry, radiobiology, and oncology translational and clinical research to achieve their mission of discovering and developing highly targeted radiopharmaceuticals.